Form 4 Filing for ARS Pharmaceuticals, Inc.

This filing reports a Form 4 filed by Margaret Ekins Smith, Chief Commercial Officer of ARS Pharmaceuticals, Inc. (SPRY). On September 1, 2026, Ms. Smith acquired 1,001,738 stock options with an exercise price of $5.77. These options are exercisable upon grant and will expire on August 31, 2036. The underlying security is Common Stock. Vesting begins on August 17, 2027, with 25% vesting on that date and the remainder vesting monthly over the subsequent three years. Ms. Smith holds these options indirectly.